ArticleEndocrine connections2025
Lower ghrelin in depression might be connected to the absence of psychotic-like experiences.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Levels of acylated and deacylated ghrelin are elevated in unmedicated patients with major depressive disorder and obesity: a cross-sectional study.Scientific reports · 2026Article
- The interactions of diet, mood, and the gut microbiome during an eight-week submarine deployment.Microbiology spectrum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) prevalence increases every year, with approximately 30% of patients remaining treatment-resistant. Ghrelin, a stomach-derived appetite-stimulating hormone, has been implicated in mood disorders, stress response, sleep-cycle regulation, reward behaviour, and neuroplasticity. However, findings in humans remain unconclusive, with reports of higher, unchanged, or lowered ghrelin concentration in patients with MDD. Psychotic-like experiences (PLEs), which are more common in the course of depression, might contribute to reported inconsistencies. This study aims to assess serum total ghrelin concentrations in individuals with depressive symptoms and investigate whether the presence of PLEs modulates the relationship. A cross-sectional study was conducted among 56 individuals screened for depressive symptoms (with patient health questionnaire-9 (PHQ-9)) and presence of PLEs in the past year (with prodromal questionnaire-16 (PQ-16)). Serum total ghrelin levels were determined by enzyme-linked immunosorbent assay (ELISA). The relationship between PHQ-9 scores and total ghrelin was analysed using linear regression and analysis of covariates (ANCOVA) when controlled for sex, age, and body mass index. Initially, depressive symptoms predicted lower ghrelin levels (P = 0.044). However, the model lost its significance when adjusted for covariates (P = 0.100). Pairwise comparisons revealed lower total ghrelin among patients with MDD but without PLEs when compared to controls (P = 0.037). No significant differences were observed within patients with a history of PLEs. This study provides preliminary evidence that PLEs modulate ghrelin secretion in patients with MDD symptoms. Further studies with larger samples are needed to clarify ghrelin's role in MDD pathophysiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.